Telomir Pharmaceuticals Inc. has announced updated compensation terms for Chief Executive Officer Erez Aminov. The approved package includes a $400,000 short-term incentive payout based on 2025 company performance, and a contingent $150,000 milestone award tied to future FDA acceptance of the company's IND submission for Telomir-1. Additionally, Aminov will receive a transaction advisory award equal to 3% of the total value of the potential acquisition of TELI Pharmaceuticals, Inc., payable in cash, equity, or both at his discretion. His base salary will be set at $500,000 effective January 1, 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-028620), on December 22, 2025, and is solely responsible for the information contained therein.